Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a medicinal chemistry paper related to the discovery of CUDC-101, Curis’s HDAC, EGFR and Her2 inhibitor, was published online in the Journal of Medicinal Chemistry and also will be published in an upcoming print version of the journal. The paper describes the structure-based rational drug design, synthesis and structure-activity relationship (SAR) of a class of novel compounds that included CUDC-101 and the identification of CUDC-101 as a clinical candidate. Related in vitro and in vivo data associated with these compounds are also included.
“We look forward to providing data for the ongoing Phase I clinical development program and beginning the next stage of clinical testing for this molecule later this year.”
“This publication underscores both the quality of the research at Curis and the productivity of our research group. Remarkably, CUDC-101 was the subject of an IND filing only two years after the synthesis of the first set of compounds within this class of molecules, and since then, a U.S. patent covering CUDC-101 has been issued,” stated Dan Passeri, Curis’ President and Chief Executive Officer. “We look forward to providing data for the ongoing Phase I clinical development program and beginning the next stage of clinical testing for this molecule later this year.”